

Index

- acne 29
- adverse reactions
 - cardiovascular 38, 39, 48
 - Marvelon 61, 63
 - oral contraceptives 18, 26, 31, 32, 48
- antithrombin
 - biphasic and triphasic formulation effects 32–5
 - coagulation factor ratio 35
- apoproteins 44
 - features 38
- apoprotein B 38
 - and heart disease 41
 - hepatic receptors 43
- atherosclerosis protection 37

- blood pressure and Marvelon 61
- body weight and Marvelon 61
- breakthrough bleeding and spotting 48
 - control assessment 51
 - definitions 58, 59
 - desogestrel:ethinyloestradiol ratio 53
 - levonorgestrel and ethinyloestradiol effects 49
 - Marvelon use 60
 - oestrogen:progestogen ratio 50–3
 - progestogen effects 53
 - triphasic preparations 50

- carbohydrate metabolism 9–14
- cardiovascular disease
 - arterial and progestogens 39
 - female hormones 38, 39
 - risk 38
- cholesterol
 - Marvelon and Microgynon effects 62
 - plasma transport 37

- coagulation factors and biphasic, triphasic formulations 32–5
- cycle control 47–55 *see also* breakthrough bleeding
 - assessment figures 55

- desogestrel 17–23
 - carbohydrate metabolism 10–13
 - glucose metabolism 14
 - HDL-cholesterol levels 57
 - potency 23
 - properties 25
 - receptor affinity 57
 - sequential formulation, hazard 35, 36
 - serum oestradiol 20
 - sex hormone binding globulin 18, 19, 21
 - structural formula 18
 - triphasic combination effects 31–6
- desogestrel:ethinyloestradiol *see also* Marvelon
 - acne 29
 - carbohydrate metabolism 10–13
 - hormonal factors affected 26–8
 - ratio and irregular bleeding 53, 54
- dihydroxytestosterone and desogestrel: ethinyloestradiol effects 28
- dysbetalipoproteinaemia 42

- ethinyloestradiol
 - doses 32
 - irregular bleeding 49, 50
 - lipoprotein effects 43
 - properties 25
 - triphasic combinations, haematological effects 31–6

TRENDS IN ORAL CONTRACEPTION

- fertility regulation and desogestrel 57-64
- fibrinogen and biphasic, triphasic formulations 32-5
- follicle stimulating hormone (FSH), desogestrel:ethinyloestradiol effects 27, 28

- glucose homeostasis, measurement 10, 13

- high density lipoprotein (HDL)
 - C, oral contraceptive effects 41
 - female levels 39
 - metabolism 38
- high density lipoprotein-cholesterol (HDL-cholesterol) 19
 - artificial elevation 63
 - Marvelon and Microgynon effects 62
 - hydroxymethylfurfural 11, 12

- lecithin:cholesterol acetyltransferase (LCAT), sex differences 43
- levonorgestrel
 - and HDL-C 41
 - irregular bleeding 49, 50
 - structural formula 18
 - triphasic formulation 31-6
- levonorgestrel:ethinyloestradiol and carbohydrate metabolism 12, 13
- libido change and Marvelon use 61
- lipid metabolism, female hormone regulation 42-4
- Lipid Research Clinics Prevalence Study 40
- Lipid Research Clinics Programme 40
- lipoproteins *see also* individual classes
 - changes with age 39
 - cholesterol and triglyceride transport 37
 - disorders, hormonal treatment 42
 - effects and apoproteins 44
 - intermediary 38
 - menstrual cycle 37
 - metabolism 38
 - serum levels and oestrogen:progestin potency 40
- low density lipoproteins (LDL) metabolism 38

- luteinizing hormone (LH) effects of desogestrel:ethinyloestradiol 27, 28
- lynestrol 17-23
 - androgenic effects 23
 - serum oestradiol 20
 - structural formula 18

- Marvelon
 - adverse reactions 61
 - composition 58
 - Microgynon comparison 58-64
 - pregnancy and compliance 60
 - serum protein effects 62, 63
- menstrual cycle *see also* cycle control
 - lipoprotein changes 43
 - triglyceride levels 40
- Microgynon, serum protein effects 62
- myocardial infarction, oral contraceptive use, risk assessment 39

- norethindrone acetate
 - hepatic lipase 43
 - lipoprotein metabolism effects 42

- 17 β -oestradiol
 - desogestrel:oestradiol effects 27
 - in serum, desogestrel and lynestrol effects 20
- oestrogens
 - myocardial infarction and sex 42
 - spotting 54
- oral contraceptives, reliability assessment 48
- oxandrolone, lipoprotein effects 42

- plasminogen, biphasic and triphasic formulations 32-5
- prealbumin, desogestrel and lynestrol effects in serum 22
- pregnancy, triglyceride and cholesterol effects 40
- progesterone, desogestrel:ethinyloestradiol effects 27, 28
- progestogen:oestrogen ratio and irregular bleeding 51-3
- prolactin and desogestrel:ethinyloestradiol effects 27, 28

TRENDS IN ORAL CONTRACEPTION

- serum glycosylated proteins
 - carbohydrate metabolism 9–14
 - estimation method 11, 12
 - low dose oral contraceptive types 12, 13
- sex hormone binding globulin 19
 - androgenization 26
 - assessment 59
 - desogestrel:ethinylloestradiol effects 28
 - desogestrel and lynestrenol effects 21
 - factors affecting 26
 - Marvelon and Microgynon effects 62, 63
- spotting 59, 60 *see also* breakthrough bleeding 59, 60

- testosterone, desogestrel:ethinylloestradiol effects 28
- triglycerides 39, 40

- Marvelon and Microgynon effects 62
- serum levels and oral contraceptives 42, 43
- triphasic preparations
 - haematological effects 31–6
 - irregular bleeding 50

- vaginal cytology
 - assessment 19
 - desogestrel and lynestrenol effects 22, 23
- very low density lipoproteins (VLDL)
 - cholesterol content and oral contraceptives 41
 - metabolism 38

- withdrawal bleeding and Marvelon use 60